Lercanidipine HCl
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Category
- Other Pharmaceuticals
Inist ST
- Membership
- VIP
- Recent Visit
- Nov 21, 2024
- Country / Year Established
-
South Korea
/
2000
- Business type
- Manufacturer
- Verified Certificate
-
16
| Product name | Lercanidipine HCl | Certification | - |
|---|---|---|---|
| Category | Other Pharmaceuticals | Ingredients | - |
| Keyword | active pharmaceutical ingredient , api , lercaniipine hcl | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | South Korea | Stock | - |
| Supply type | - | HS code | - |
Product Information
| Category |
Antihypertensive
| Spec |
IHS
| Description |
Lercanidipine is an antihypertensive (blood pressure lowering) drug. It belongs to the dihydropyridine class of calcium channel blockers, which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. This lowers the blood pressure and allows the heart to work more efficiently.
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- Kim Kuk-hyun
- Address
- Geumwang-Eup, 500 Shinaero , Eumseong-gun, Chungcheongbuk-do, Korea
- Product Category
- Pharmaceuticals
- Year Established
- 2000
- Company introduction
-
Having persistent enthusiasm, INIST ST is trying to contribute to the society and community by delivering healthier life from age 0 to 110 years through research and innovation. Since its establishment in 2000, INIST ST has been accomplishing rapid growth with passion, confidence and trust between customers and the company. INIST ST has developed non-cytotoxic anti-cancer, high quality generic & value-added API and supplied to the domestic and overseas markets. INIST ST has intensive R&D function in exploration of drug candidate and process development of small molecules. As result of those efforts, INIST ST has achieved multiple crystal and process patents and become partner of several government sponsoring development projects.
- Main Markets
-
Japan
Taiwan
Turkey
U.S.A
- Main Product
